At RARE-NL, we believe that collaboration is essential to accelerate the development of therapies for rare diseases and the use of drug repurposing. In a field filled with complex challenges, innovative and sustainable solutions are required. By bringing together academic institutions, patient organizations, and pharmaceutical and biotech companies—both large and small—we create a value chain that spans the entire trajectory: from fundamental research to the final approval of medicines and patient access.

RARE-NL provides a platform where expertise on socially responsible access to these medicines converges. Even in the early stages of the development process, we can offer advice on what researchers need to consider to make medicines affordable and accessible to patients. As projects progress toward clinical phases, RARE-NL can assist in setting up public-private partnerships (PPPs) under socially responsible conditions. For medicines that have reached the market through industry efforts, RARE-NL offers clinicians, pharmacists, and researchers expertise on innovative reimbursement pathways.

In every case, we work to bring medicines closer to patients, always in a socially responsible way. At the same time, we explore how these cases can provide insights to structurally improve the healthcare system.

Levels of collaboration with RARE-NL

1) Sharing knowledge & expertise

RARE-NL facilitates knowledge sharing through various channels, such as educational platforms, our website, events, presentations, and the FAST Forum. Questions can be directed to team members or submitted via the contact form.

2) Non-binding advice

When needed, we provide free advice regarding specific cases, potentially involving external expertise. This could include development trajectories for medicines for rare diseases, drug repurposing projects, or reimbursement pathways.

3) Long-term collaboration

We support the creation of strategic and sustainable collaborations to realize innovative solutions and products. RARE-NL offers guidance, for example, in applying for support from organizations like the EMA (European Medicines Agency) and the CBG (Medicines Evaluation Board).

4) Project-BV

Various options are available to ensure the sustainable availability of medicines. From pharmacy compounding to formal registration, RARE-NL is committed to making essential medicines available and keeping them accessible. This could also involve setting up project-specific entities (Project-BV) under socially responsible conditions. By formalizing collaborations in such entities, we strengthen collective impact and engagement.

Get in touch with RARE-NL and discover the added value of this collaboration.